Registrieren
Registierung erfolgt in Kürze...
Details werden geladen...
Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights | The Manila Times
- Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 -
Ähnliche Seiten
Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) | The Manila Times
https://www.manilatimes.net/2026/07/20/tmt-newswire/globenewswire/dyne-therapeutics-announces-us-fda-acceptance-of-biologics-license-application-bla-for-z-rostudirsen-in-exon-51-duchenne-muscular-dystrophy-dmd/2387516OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results | The Manila Times
https://www.manilatimes.net/2026/07/28/tmt-newswire/globenewswire/opko-health-reports-second-quarter-2026-business-highlights-and-financial-results/2392513Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates | The Manila Times
https://www.manilatimes.net/2026/07/31/tmt-newswire/globenewswire/werewolf-therapeutics-reports-second-quarter-2026-financial-results-and-recent-corporate-updates/2395829
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights | The Manila Times
https://www.manilatimes.net/2026/06/03/tmt-newswire/globenewswire/avalyn-reports-first-quarter-2026-financial-results-and-recent-business-highlights/2357667Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results | The Manila Times
https://www.manilatimes.net/2026/06/29/tmt-newswire/globenewswire/helus-pharma-reports-recent-business-highlights-and-fiscal-year-2026-financial-results/2374792